NCT06038409 Ketamine Treatment Plans for Chronic Conditions
| NCT ID | NCT06038409 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RIVER Foundation |
| Condition | Chronic Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2029-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-01-01 with a primary completion date of 2029-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.
Eligibility Criteria
Inclusion Criteria: Must have an identifiable chronic condition. Exclusion Criteria: Healthy population
Contact & Investigator
Edward Lesofski, MS
STUDY DIRECTOR
RIVER Foundation
Frequently Asked Questions
Who can join the NCT06038409 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06038409 currently recruiting?
Yes, NCT06038409 is actively recruiting participants. Contact the research team at ed@riverofchange.org for enrollment information.
Where is the NCT06038409 trial being conducted?
This trial is being conducted at Helena, United States.
Who is sponsoring the NCT06038409 clinical trial?
NCT06038409 is sponsored by RIVER Foundation. The principal investigator is Edward Lesofski, MS at RIVER Foundation. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.